Lumosa Therapeutics has announced encouraging findings from two Phase 2 clinical trials of its innovative stroke treatment, LT3001 (Odatroltide). The trials demonstrated significant functional...
Research presented at the American Stroke Association’s International Stroke Conference 2026 reveals that a novel neuroprotective drug, loberamisal, may significantly improve recovery outcomes for...